David Gryska Net Worth

The estimated Net Worth of David W Gryska is at least $15.7 Million dollars as of 13 February 2023. Mr. Gryska owns over 8,750 units of Seagen Inc stock worth over $11,214,827 and over the last 20 years he sold SGEN stock worth over $4,062,405. In addition, he makes $445,631 as Independent Director at Seagen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gryska SGEN stock SEC Form 4 insiders trading

David has made over 40 trades of the Seagen Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of SGEN stock worth $321,125 on 13 February 2023.

The largest trade he's ever made was selling 150,000 units of Seagen Inc stock on 17 November 2020 worth over $360,000. On average, David trades about 6,308 units every 39 days since 2005. As of 13 February 2023 he still owns at least 49,003 units of Seagen Inc stock.

You can see the complete history of Mr. Gryska stock trades at the bottom of the page.

David Gryska biography

David W. Gryska serves as Independent Director of the Company. Mr. Gryska has years of experience as Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios, Inc., and Cardiac Pathways Corporation. He brings to the Board valuable and relevant experience as a senior financial executive at life sciences and biotechnology companies engaged in financings, global expansion and other strategic transactions. He also has extensive knowledge of accounting principles and financial reporting rules and regulations, tax compliance and oversight of the financial reporting processes of several large, publicly-traded corporations, which assists Mr. Gryska in fulfilling his duties as chair of our Audit Committee.

What is the salary of David Gryska?

As the Independent Director of Seagen Inc, the total compensation of David Gryska at Seagen Inc is $445,631. There are 12 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.

How old is David Gryska?

David Gryska is 64, he's been the Independent Director of Seagen Inc since 2005. There are 2 older and 18 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.

What's David Gryska's mailing address?

David's mailing address filed with the SEC is 21823 30TH DR. SE, , BOTHELL, WA, 98021.

Insiders trading at Seagen Inc

Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.

What does Seagen Inc do?

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Complete history of Mr. Gryska stock trades at Aerie Pharmaceuticals Inc, GW Pharmaceuticals, Incyte, PDL Biopharma Inc, and Seagen Inc

Seagen Inc executives and stock owners

Seagen Inc executives and other stock owners filed with the SEC include:

• Clay Siegall,
  Chairman of the Board, President, Chief Executive Officer
• Roger Dansey,
  Chief Medical Officer
• Todd Simpson,
  Chief Financial Officer
• Jean Liu,
  Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Vaughn Himes,
  Chief Technical Officer
• Dr. Clay B. Siegall,
  Co-Founder, Chairman, Pres & CEO
• Dr. Roger D. Dansey M.D.,
  Chief Medical Officer & Interim CEO
• Jean I. Liu,
  Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.
• Jean I. Liu J.D., M.S.,
  Chief Legal Officer
• Charles R. Romp,
  Exec. VP of Commercial U.S.
• Todd E. Simpson,
  Chief Financial Officer
• Felix Baker,
  Lead Independent Director
• David Gryska,
  Independent Director
• John Orwin,
  Independent Director
• Nancy Simonian,
  Independent Director
• Alpna Seth,
  Independent Director
• Daniel Welch,
  Independent Director
• Marc Lippman,
  Independent Director
• Ted Love,
  Director
• David Caouette,
  VP of Corp. Communications
• Dr. Vaughn B. Himes,
  Chief Technical Officer
• Christopher P. Pawlowicz,
  Exec. VP of HR
• Matt Skelton,
  VP of Marketing
• Natasha A. Hernday,
  Exec. VP of Corp. Devel. & Alliance Management
• Nancy Whiting B.Sc., Pharm.D.,
  Exec. VP of Corp. Strategy, Alliances & Communications
• Peggy Pinkston,
  VP of Investor Relations
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Felixbaker Julian Baker Bro...,
  
• Srinivas Akkaraju,
  Director
• Eric Dobmeier,
  Vice President,
• Bros. Advisors Lp667, L.P.B...,
  
• Sandra M Swain,
  
• Morgan Partners Bhca Lpjpmp...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Robin G Taylor,
  Chief Commercial Officer
• Felix667, L.P.Baker Julian ...,
  
• John Peter Mclaughlin,
  Director
• Felix Baker,
  Director
• Morris Rosenberg,
  SVP, Development
• Bruce J. Seeley,
  EVP, Commerical
• Felix667, L.P.Baker Brother...,
  
• Thomas C Reynolds,
  Chief Medical Officer
• Christopher S. Boerner,
  SVP, Commercial
• Brothers Life Sciences Capi...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Holdings, Inc.H&Q Employee ...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Darren S Cline,
  SVP, Commercial
• Morgan Partners Bhca Lpjpmp...,
  
• Felixbaker Julian Baker Bro...,
  
• Franklin M Berger,
  Director
• Morgan Partners Bhca Lp Jp,
  10% owner
• Daniel Floyd Jr Hoth,
  Director
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Jonathan Gallen,
  10% owner
• Management Partners Vi Llcd...,
  
• Pamela A Trail Smith,
  Chief Scientific Officer
• Brothers Life Sciences Capi...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Biotech Capital Ii (Z) (Gp)...,
  
• Amy Sing,
  Sr. Director Medical Affairs
• Michael Powell,
  Director
• Biotech Capital Iii (Z) (Gp...,
  
• Tim Carroll,
  CFO
• Investment Llc Cascade,
  
• Douglas Southern,
  Director
• Karl Erik Hellstrom,
  Director
• Michael Mcdonald,
  Chief Medical Officer
• Morgan Partners Bhca Lpjpmp...,
  
• Peter Senter,
  Vice President, Chemistry
• H Perry Fell,
  Chairman
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• David R Epstein,
  CEO
• Charles R Romp,
  EVP, Commercial U.S.